Company Executives Available to Meet with
Investment Professionals January 8-10 in San Francisco
Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the
“Company”), a clinical-stage, fully-integrated biotherapeutics
company using its proprietary DIAMOND® artificial intelligence and
data mining platform to develop cell therapies with a focus on
immuno-oncology, reports favorable safety and tolerability from the
first patient 23 days after Deltacel™ infusion in the Phase 1
clinical trial for treatment of stage 4 metastatic non-small cell
lung cancer (NSCLC) at Beverly Hills Cancer Center, located in
Beverly Hills, California, USA. Specifically, laboratory test
results and observations by clinical staff identified no adverse
events and confirmed that Deltacel is being well tolerated with
initial safety profile. Continued monitoring of safety and
tolerability will provide more insights as the trial enrolls
additional patients.
Kiromic expects to report preliminary efficacy results from this
patient by the end of January 2024. Two more patients are expected
to be enrolled between January and February 2024.
“Our first-in-human clinical trial of Deltacel is proceeding
very well and on plan,” said Pietro Bersani, Chief Executive
Officer of Kiromic. “With no adverse events observed during the
first 23 days post-treatment, we have strong indication that
Deltacel is well tolerated. We look forward to discussing updates
with members of the investment community during our meetings next
week in San Francisco, concurrent with the 42nd Annual J.P. Morgan
Healthcare Conference.”
Investment professionals interested in meeting with Mr. Bersani,
Chief Financial Officer Brian Hungerford and Chief Scientific
Officer Dr. Leonardo Mirandola at LHA’s offsite event being held
January 8-10 should contact Tirth Patel at tpatel@lhai.com.
"We are very pleased to see favorable initial safety and
tolerability data from the first patient treated in our Deltacel-01
study," said Dr. Afshin Eli Gabayan, Medical Oncologist, Medical
Director, and Principal Investigator at Beverly Hills Cancer
Center. “Seeing no adverse events reported 23 days after Deltacel
infusion provides early validation that this novel cell therapy is
well tolerated when combined with low dose radiation for lung
cancer patients. We look forward to further evaluating optimal dose
level, efficacy, and long-term safety outcomes as additional
patients are enrolled and treated. If this promising initial data
is replicated in more patients, Deltacel could become a new
alternative treatment option for NSCLC patients.”
About Deltacel-01
In Kiromic’s open-label Phase 1 clinical trial, titled “Phase 1
Trial Evaluating the Safety and Tolerability of Gamma Delta T Cell
Infusions in Combination With Low Dose Radiotherapy in Subjects
With Stage 4 Metastatic Non-Small Cell Lung Cancer” (NCT06069570),
patients with stage 4 NSCLC will receive two intravenous infusions
of Deltacel with four courses of low-dose, localized radiation over
a 10-day period. The primary objective of the study is to evaluate
safety, while secondary ones include objective response,
progression-free survival, overall survival, time to progression,
time to treatment response and disease control rates.
About Deltacel™
Deltacel (KB-GDT-01) is an investigational gamma delta T-cell
(GDT) therapy currently in the Deltacel-01 Phase 1 trial for the
treatment of NSCLC. An allogeneic product consisting of unmodified,
donor-derived gamma delta T cells, Deltacel is the leading
candidate in Kiromic’s GDT platform. Deltacel is designed to
exploit the natural potency of GDT cells to target solid cancers,
with an initial focus on NSCLC, the most prevalent type of lung
cancer and representing about 80% to 85% of lung cancer cases. Data
from two preclinical studies demonstrated Deltacel’s favorable
safety and efficacy profile when it was combined with low-dose
radiation.
About Kiromic BioPharma
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated
biotherapeutics company using its proprietary DIAMOND® artificial
intelligence (AI) 2.0 target discovery engine to develop and
commercialize cell therapies focusing on immuno-oncology. Kiromic
is developing a multi-indication allogeneic cell therapy platform
that exploits the natural potency of Gamma Delta T-cells to target
solid tumors. Kiromic’s DIAMOND® AI is where data science meets
target identification to dramatically compress the years and
hundreds of millions of dollars required to develop a live drug.
The Company maintains offices in Houston, Texas. To learn more,
visit www.kiromic.com and connect with us on Twitter and
LinkedIn.
About Beverly Hills Cancer Center
As a private, academic, community-based cancer center, Beverly
Hills Cancer Center not only provides the latest state-of-the-art
cancer treatments all under one roof, but also provides leading
clinical trials and research, attracting patients globally. By
providing access to groundbreaking clinical trials, the Beverly
Hills Cancer Center offers patients the opportunity to participate
in the most advanced cancer treatments currently in development in
the world. Beverly Hills Cancer Center is composed of an
internationally recognized multidisciplinary medical team
consisting of Medical Oncologists, Radiation Oncologists,
Radiologists, Hematologists and Internists who provide exceptional
patient care and support services including a robust and highly
efficient team of clinical research professionals. More information
is available on: www.BHCancerCenter.com.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. Kiromic makes such
forward-looking statements pursuant to the safe harbor provisions
of the United States Private Securities Litigation Reform Act,
Section 21E of the Securities Exchange Act of 1934, as amended, and
other federal securities laws. All statements other than statements
of historical facts are forward-looking statements. In some cases,
you can identify forward-looking statements by terms such as:
“will,” “potential,” “could,” “can,” “believe,” “intends,”
“continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,”
or the negative of these terms or other comparable terminology.
These forward-looking statements include, but are not limited to,
statements regarding: Kiromic’s ability to achieve its objectives
and Kiromic’s financing strategy and availability of funds. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
levels of activity, performance, or achievements to be materially
different from the information expressed or implied expressed or
implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, the risks and
uncertainties discussed in our Annual Report on Form 10-K for the
year ended December 31, 2022, and as detailed from time to time in
our other SEC filings. You should not rely upon forward-looking
statements as predictions of future events. Although we believe
that the expectations reflected in the forward-looking statements
are reasonable, we cannot guarantee that the future results, levels
of activity, performance, or events and circumstances reflected in
the forward-looking statements will be achieved or occur. Moreover,
neither we nor any other person assumes responsibility for the
accuracy and completeness of the forward-looking statements. Such
forward-looking statements relate only to events as of the date of
this press release. We undertake no obligation to update any
forward-looking statements except to the extent required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240105590033/en/
Kiromic BioPharma Linda Phelan Dyson, MPH Global Head,
Corporate Communications ldyson@kiromic.com 281-468-7683
LHA Investor Relations Tirth T. Patel tpatel@lhai.com
212-201-6614
Beverly Hills Cancer Center Sharon Neman Chief Strategy
Officer SN@BHCancerCenter.com 310-432-8925
Kiromic BioPharma (NASDAQ:KRBP)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Kiromic BioPharma (NASDAQ:KRBP)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024